Johnson & Johnson is a Buy as newer medicines and MedTech growth offset STELARA’s decline. The stock looks fairly valued to slightly attractive with strong cash generation and a broad pipeline.
Johnson & Johnson (JNJ) is a Buy for moderate-risk investors with a medium-term horizon. The thesis rests on a broad healthcare platform, strong cash generation, and accelerating growth in newer medicines that is offsetting the steep decline of STELARA. JNJ reported $25.3B of Q2 2026 sales, up 5.6% operationally, and raised its 2026 operational sales growth outlook to 6.5%-7.1% with a midpoint of $100.6B.
The growth engine is increasingly visible. DARZALEX sales grew 17.6%, TREMFYA grew 71.0%, CARVYKTI grew 47.7%, and RYBREVANT with LAZCLUZE grew 61.6% in Q2. MedTech adds diversification through cardiovascular, surgery, orthopaedics, and vision, although its 3.6% operational growth lagged Innovative Medicine's 6.8%.
The principal tension is valuation. JNJ trades at 30.8x trailing earnings and 21.0x forward earnings, while its PEG ratio is 2.8x and earnings growth over the latest comparable period was -0.9%. That is not a bargain multiple, but the $12.31 next-year EPS estimate, $29.4B of free cash flow, and $279.82 analyst target support measured upside rather than a speculative leap.
Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson employs approximately 138,200 people and operates through two segments: Innovative Medicine and MedTech. The 2025 Form 10-K describes a global healthcare company involved in research, development, manufacturing, and sales across prescription medicines and medical technologies.
Innovative Medicine generated $60.4B of 2025 revenue, or 64.1% of the company's total. MedTech generated $33.8B, or 35.9%. This mix gives JNJ exposure to both pharmaceutical product cycles and procedure-driven device markets. The combination is less concentrated than a pure-play drug company, though it also makes the business harder to value with a single industry multiple.
Innovative Medicine remains the primary earnings engine. Q2 sales reached $16.4B, up 6.8% operationally despite a roughly 760 basis point STELARA headwind. Oncology generated $7.4B, immunology $3.8B, neuroscience $2.3B, and other therapeutic areas $2.8B in the quarter.
Oncology is the strongest part of the pharmaceutical portfolio. DARZALEX remained the largest product with quarterly sales above $4B. CARVYKTI, TECVAYLI, and TALVEY all delivered high growth, while RYBREVANT and LAZCLUZE benefited from launch uptake in lung cancer. Management said 80% of multiple myeloma patients receive at least one JNJ medicine during their treatment journey, illustrating the commercial depth of the franchise.
Immunology is in transition. STELARA is losing share to biosimilars and newer classes, but TREMFYA grew 71.0% as inflammatory bowel disease indications expanded. The combination of TREMFYA and the newer oral therapy ICOTYDE gives JNJ two distinct positions in psoriasis, while IMAAVY adds an emerging rare-disease opportunity.
MedTech generated $8.9B of Q2 sales, up 3.6% operationally. Vision grew 5.6%, Shockwave grew 14.7%, and orthopaedics grew 4.2%. Cardiovascular grew 3.1%, held back by a 2.0% decline in Abiomed and inventory pressure in China. Surgery grew 2.3%, with commercial investment and competitive pressure limiting the pace.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
DARZALEX is JNJ's flagship product and the clearest example of its commercial strength. The medicine generated more than $4B of Q2 sales and grew 17.6%, supported by five percentage points of share gains across treatment lines and nearly 11 percentage points of share gains in frontline treatment.
The franchise has meaningful concentration risk. DARZALEX and DARZALEX FASPRO represented approximately 15.0% of 2025 revenue, and the two principal patent families licensed from Genmab expire in the United States in 2029. JNJ owns separate patent portfolios for DARZALEX FASPRO and DARZALEX IV, while European protection extends to 2031 or 2032 in select countries.
The wider product group softens that risk. CARVYKTI grew 47.7%, TECVAYLI grew 56.1%, and TALVEY grew 62.6% in Q2. RYBREVANT with LAZCLUZE grew 61.6%, while TREMFYA, SPRAVATO, and CAPLYTA grew 71.0%, 40.0%, and 70.9%, respectively. JNJ is building a portfolio rather than asking one aging blockbuster to carry the entire company, which is the more durable way to run a pharmaceutical business.
JNJ's competitive advantage comes from scale, clinical breadth, and the ability to commercialize products across hospitals, physicians, wholesalers, retailers, and specialty-care settings. The 2025 annual report records 51 approvals, 32 submissions, 17 positive key study readouts, and 11 new Phase 3 programs.
The current pipeline is tied to areas with measurable commercial traction. ICOTYDE had more than 10,000 patients initiated on therapy by Q2. CAPLYTA new patient starts increased 122% year over year. In MedTech, VARIPULSE had treated more than 85,000 atrial fibrillation patients worldwide, while CARTOSOUND SONATA added AI-powered imaging and mapping capabilities.
That statement is supported by the breadth of Q2 growth, though it remains a management target rather than a guarantee. The planned Firefly Bio acquisition adds a KRAS-focused oncology platform, and the planned DePuy Synthes separation by mid-2027 could sharpen the strategic focus of the remaining MedTech portfolio.
JNJ operates a global manufacturing and distribution network across virtually all major markets. Its 2025 Form 10-K states that essential raw materials are generally available from multiple sources, reducing dependence on a single supplier for most inputs.
Q2 showed both operating leverage and friction. Cost of goods sold improved by 30 basis points, while research and development costs leveraged by 40 basis points. Selling, marketing, and administrative expenses deleveraged by 60 basis points because JNJ increased investment behind new launches. Tariffs affected MedTech margins, and China inventory reduced electrophysiology growth by an estimated 400 basis points.
The company also announced an investment of more than $1B to expand U.S. vision manufacturing, packaging, and distribution capacity. That spending supports ACUVUE and TECNIS growth, although it places near-term demands on capital and execution.
The global pharmaceutical market was estimated at approximately $1.78T in 2025 and is projected to reach $2.62T by 2031, representing a 6.7% compound annual growth rate from 2026 through 2031. JNJ's 2026 operational sales growth outlook of 6.5%-7.1% is therefore aligned with the broader market estimate, before considering the company's above-market growth in selected brands.
The industry is shifting toward biologics, precision medicine, specialty therapies, and biosimilars. FDA data showed 38 BLA approvals in fiscal 2025, with biosimilars representing more than 40% of BLA approvals in both fiscal 2024 and fiscal 2025. That trend creates opportunity for innovative therapies while increasing pressure on mature biologics such as STELARA.
Medical technology benefits from procedure growth, premium devices, and digital integration. JNJ's investments in robotic surgery, pulsed-field ablation, intravascular lithotripsy, and premium intraocular lenses place it in markets where product innovation can support pricing and share gains.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
JNJ serves several customer groups. Innovative Medicine sells through retailers, wholesalers, distributors, hospitals, and healthcare professionals. MedTech products are purchased and used primarily by hospitals, surgeons, physicians, nurses, eye-care professionals, clinics, and surgical centers.
The commercial decision is usually made by a combination of prescribers, hospital systems, insurers, pharmacy benefit managers, and patients. That structure creates strong regulatory and clinical barriers to entry, but it also exposes JNJ to formulary decisions, reimbursement limits, government price controls, and procedure-volume changes.
Q2 results show how customer behavior affects each segment. TREMFYA gained share across indications, while Abiomed faced lower U.S. procedure volumes as physicians became more selective. ACUVUE growth remained broad across regions, and ICOTYDE had more than 10,000 therapy starts, providing concrete evidence of early prescriber and patient adoption.
In Innovative Medicine, JNJ competes with AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GSK, Merck, Novartis, Pfizer, Roche, and Sanofi. The most direct competitive pressure varies by therapeutic area: Merck, Bristol Myers Squibb, AstraZeneca, and Roche are important oncology rivals, while AbbVie, Amgen, and Sanofi compete in immunology.
In MedTech, the competitive set includes Boston Scientific, Medtronic, Stryker, Intuitive Surgical, Alcon, Bausch & Lomb, Cooper Companies, and Smith & Nephew. JNJ's advantage is breadth across drugs and devices, while focused rivals can concentrate more capital and management attention on a narrower category.
JNJ's recent performance shows both sides of that trade-off. Innovative Medicine grew 6.8% in Q2 despite STELARA erosion, but MedTech grew 3.6% and faced competitive pressure in electrophysiology, surgical energy, endoscopic cutters, and heart recovery. The diversified model reduces dependence on any single market, but it does not eliminate execution risk.
JNJ faces a regulatory environment shaped by drug-pricing scrutiny, biosimilar adoption, cybersecurity rules, data-privacy requirements, and increasingly complex product approvals. The 2025 Form 10-K identifies the Inflation Reduction Act, Medicare price negotiations, and government pressure on healthcare costs as material influences on the pharmaceutical business.
International operations add currency, political, legal, and reimbursement risk. JNJ reported Q2 operational growth of 8.9% in the United States and 3.6% outside the United States in Innovative Medicine. MedTech grew 3.9% in the United States and 3.2% outside the United States, while China inventory and value-based purchasing reduced performance.
The macro backdrop also includes aging populations and rising chronic-disease prevalence. Those forces support long-term demand for oncology, immunology, neuroscience, cardiovascular, vision, and orthopaedic products. The offset is payer pressure: healthcare systems want better outcomes at lower cost, which rewards strong clinical evidence and penalizes weak differentiation.
A B- balance sheet score reflects solid cash generation, but JNJ still carries enough leverage and capital demands to keep financial flexibility from being pristine.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →A B+ income statement grade is supported by $25.3B in Q2 sales, 5.6% operational growth, and strength in DARZALEX, TREMFYA, and CARVYKTI.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →An A- estimates outlook is anchored by raised 2026 operational sales growth guidance of 6.5%-7.1% and a midpoint of $100.6B.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →A B valuation grade reflects 30.8x trailing earnings and 21.0x forward earnings, which are balanced by $12.31 next-year EPS and $29.4B of free cash flow.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s $279.82 analyst target sits above the $275 fair value, suggesting modest upside rather than a deep discount.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Johnson & Johnson is executing a credible transition from dependence on mature products toward a broader portfolio of oncology, immunology, neuroscience, cardiovascular, surgery, and vision assets. Q2 provided concrete evidence: $25.3B of sales, 5.6% operational growth, strong performance from newer medicines, and raised 2026 guidance.
The investment case is not built on a cheap headline multiple. It is built on the combination of $29.4B of free cash flow, a 21.0x forward P/E, a wide product base, and estimates that place EPS at $12.36 in 2027 and $18.12 in 2030. The main risks are visible rather than hidden: STELARA erosion, patent concentration around DARZALEX, regulatory pricing pressure, litigation costs, and uneven MedTech growth.
For a medium-term investor, those facts support a Buy at disciplined prices, not an open-ended chase. JNJ has the financial capacity and commercial scale to keep compounding, but the best returns will come from respecting valuation while the new product cycle proves itself.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Johnson & Johnson (JNJ) drops after a mixed Q3 earnings report. The company beat adjusted EPS and revenue estimates and raised guidance, but reported profit fell and MedTech sales faced Middle East-related pressure, prompting investors to reassess the stock’s premium valuation.
Strong quarterly results didn’t translate into broad gains, with Western Digital, American Express and Newmont all falling despite solid earnings. Kinder Morgan stood out as the week’s winner, rising after an EPS beat and a record natural gas project backlog.
Fresh data showed a split US economy: business activity and hiring stayed resilient, but housing weakened sharply under high borrowing costs. Strong PMI readings and low jobless claims pointed to solid growth, while rising price pressures kept the Federal Reserve’s higher-for-longer stance in focus.